Simcere Pharmaceutical jumps most in two months on Roche tie-up
02/09/2026 08:16
BUZZ-Simcere Pharmaceutical jumps most in two months on Roche tie-up ** Shares of generic drugs producer Simcere Pharmaceutical Group 2096.HK jump 7.9% to HK$11.86, on course for the biggest one-day pct rise since July 2
** Stock hits the highest level since August 24, on track to snap four straight sessions of losses
** Top pct gainer in Hang Seng Biotech Index .HSBIO, which is up 0.4%
** Switzerland's Roche ROPC.S will pay $75 million upfront to Simcere Pharmaceutical for rights to an experimental blood cancer drug, the Chinese drugmaker said on Tuesday
** Simcere is also eligible to receive up to about $1.46 billion in payments for unspecified milestones
** YTD, stock down 1.6%, benchmark Hang Seng Index .HSI down 1.5%
(Reporting by Donny Kwok)
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660